COPD trial run by an international company based in Italy, with a strong focus on research, development, production and the commercialisation of innovative medicines in Respiratory.
The DynaPort MoveMonitor was used in a Phase IIb pharmaceutical trial to evaluate the efficacy and safety of a medication for the treatment of patients with COPD.
For this multicentre and multinational clinical trial, 98 patients were randomized in 30 sites.
Study objectives included completing the e-PROactive questionnaire daily, using an electronic device configured for the study, and wearing a physical activity monitor device (DynaPort MoveMonitor), to collect physical activity information.